This article provides an in-depth overview of Hematoporphyrin HCl, a compound with CAS numbers 17696-69-4 and 17471-45-3. It explores its chemical properties, applications, synthesis methods, safety considerations, and regulatory status. By delving into these aspects, the article aims to offer a comprehensive understanding of this compound, its significance in various fields, and the knowledge necessary for its safe and effective use.
Hematoporphyrin HCl, also known as hematoporphyrin dihydrochloride, is a porphyrin derivative that has gained significant attention in medical, pharmaceutical, and industrial applications. It is a dark red to purple crystalline powder that is soluble in water and alcohol. This compound is derived from heme, the iron-containing prosthetic group found in hemoglobin, and is widely used in photodynamic therapy for the treatment of various cancers.
Hematoporphyrin HCl has a molecular formula of C34H32N4O4Cl2 and a molecular weight of 620.9 g/mol. It is a complex organic molecule that contains a porphyrin ring, which is a macrocyclic tetrapyrrole. The presence of the porphyrin ring in Hematoporphyrin HCl is responsible for its characteristic absorption and emission properties in the visible and near-infrared regions of the electromagnetic spectrum. These properties make it useful in photodynamic therapy, where it is activated by light to produce reactive oxygen species that can kill cancer cells.
One of the primary applications of Hematoporphyrin HCl is in photodynamic therapy (PDT), a treatment modality that combines the use of a photosensitizer, light, and oxygen to kill cancer cells. Hematoporphyrin HCl is used as a photosensitizer in PDT for the treatment of superficial and early-stage cancers, such as skin cancer, esophageal cancer, and bladder cancer. It is also used in ophthalmology for the treatment of certain types of eye cancer.
In addition to its use in medicine, Hematoporphyrin HCl has applications in other fields. It is used in the diagnosis of prostate cancer through a procedure called photodynamic diagnosis. It is also employed in the detection of endometrial cancer and in the treatment of actinic keratosis, a precancerous skin condition.
The synthesis of Hematoporphyrin HCl involves a multi-step process that typically starts with the preparation of porphyrin precursors. These precursors are then converted into the desired porphyrin, which is finally converted into Hematoporphyrin HCl. The process requires careful control of reaction conditions to ensure the purity and quality of the final product. The synthesis of Hematoporphyrin HCl is complex and requires specialized equipment and expertise.
Hematoporphyrin HCl is considered a hazardous substance due to its potential for causing skin and eye irritation. It is important to handle this compound with appropriate safety measures, including the use of gloves, goggles, and a fume hood. The compound is also photosensitizing, which means it can cause skin reactions when exposed to sunlight or artificial light sources.
In terms of regulatory status, Hematoporphyrin HCl is subject to various regulations depending on its intended use. For medical applications, it is regulated by the Food and Drug Administration (FDA) in the United States. In Europe, it is regulated by the European Medicines Agency (EMA). Compliance with these regulations is essential for the safe and effective use of Hematoporphyrin HCl.
Hematoporphyrin HCl, with CAS numbers 17696-69-4 and 17471-45-3, is a versatile compound with significant applications in medicine and other fields. Its unique chemical properties make it an effective photosensitizer in photodynamic therapy, while its potential for use in diagnostic procedures adds to its utility. Understanding the synthesis, safety considerations, and regulatory status of Hematoporphyrin HCl is crucial for its safe and effective use.
Keywords: Hematoporphyrin HCl, CAS 17696-69-4, CAS 17471-45-3, photodynamic therapy, porphyrin derivative, safety considerations, regulatory status.